| Literature DB >> 31007973 |
Ahmad Kamal Ghanimi Zamli1, Noor Shirlyna Irma Ngah1, Tan Chew-Ean1, Julieana Muhammed1, Wan-Hazabbah Wan Hitam1, Adil Hussein1, Embong Zunaina1.
Abstract
Introduction Ocular syphilis is a sight-threatening condition. It can occur at any stage of syphilis infection, which present either with acute inflammation during the primary, secondary, and early latent stages or with chronic inflammation during tertiary infection, affecting virtually every ocular structure. This study was to report on the clinical presentation of ocular syphilis that presented to eye clinic Hospital Universiti Sains Malaysia. Methodology This was a retrospective study where medical records of ocular syphilis patients who attended eye clinic in Hospital Universiti Sains Malaysia from January 2013 to June 2017 were reviewed. Results A total of 10 patients (13 eyes) with ocular syphilis were identified out of 106 cases that presented with ocular inflammation. The mean age of presentation was 69.8 ± 6.4 years and seven of them (70%) were female. All patients were Malay and human immunodeficiency virus (HIV) was negative. The ocular manifestations included panuveitis (four eyes, 30.8%), anterior uveitis (two eyes, 15.4%), posterior uveitis (seven eyes, 53.8%) and optic neuritis (two eyes, 15.4%). Seven (53.8%) eyes presented with visual acuity of worse than 6/60, five (38.5%) eyes had visual acuity between 6/15 to 6/60, and one (7.7%) eye had visual acuity of 6/12 or better. Nine patients received an intravenous benzylpenicillin regime and one patient received an intramuscular penicillin injection. Out of 13 eyes affected, 11 (84.6%) eyes had improved visual acuity of at least one Snellen line after treatment. Visual acuity of 6/12 or better increased to four (30.8%) eyes. Conclusions Posterior uveitis was the commonest presentation of ocular syphilis in HIV-negative patients. Early detection and treatment of ocular syphilis can result in resolution of inflammation and improvement of vision.Entities:
Keywords: human immunodeficiency virus (hiv) negative; neurosyphilis; ocular syphilis; uveitis
Year: 2019 PMID: 31007973 PMCID: PMC6453624 DOI: 10.7759/cureus.4015
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Clinical profile of patients with ocular syphilis
RE, right eye; LE left eye; BE, both eyes; BOV, blurring of vision; HPT, hypertension; IHD, ischemic heart disease; CKD, chronic kidney disease; CVA, cerebrovascular accident; N, normal; KP, keratic precipitates; BK, bullous keratopathy; SP, seclusio pupillae; PS, posterior synechia; IOP, intraocular pressure; mmHg, millimetres of mercury; CDR, cup-disc-ratio; PACG, primary angle closure glaucoma; AC, anterior chamber; VH, vitreous haemorrhage; DH, dot haemorrhage; BH blot haemorrhage; OD, optic disc; IV, intravenous; IM, intramuscular; MU, megaunit; BCVA, best corrected visual acuity; NPL, no perception of light; CF, counting fingers; HM, hand movement; ft, feet
| No | Age | Sex | Eye | Ocular symptoms | Duration (months) | High-risk behaviour | Comorbid | Ocular examination | Clinical diagnosis | Treatment | Initial BCVA | Final BCVA | Follow-up duration (months) | |||
| RE | LE | RE | LE | RE | LE | |||||||||||
| 1 | 61 | F | RE | BOV | 1 week | Husband has syphilis | Nil | KP, AC cells | N | RE anterior uveitis | IM penicillin 2.4 MU weekly for 3 weeks | 6/24 | 6/7.5 | 6/7.5 | 6/7.5 | 48 |
| 2 | 69 | F | RE | RE BOV | 36 | Unknown | Nil | KP, SP, AC cells, chorioretinitis, macular edema, IOP 12 mmHg, CDR 0.9 | BK, IOP 26mmHg | RE panuveitis, BE PACG | IV benzylpenicillin 4 MU 4 hourly for 2 weeks | 6/36 | NPL | 6/15 | NPL | 40 |
| 3 | 67 | F | BE | BOV, Eye redness, Eye pain | 2 | Unknown | Nil | Chorioretinitis, VH | Chorioretinitis, Chorioretinal scar | BE posterior uveitis | IV benzylpenicillin 3 MU 4 hourly for 2 weeks | 6/45 | 6/12 | HM | 6/9 | 40 |
| 4 | 71 | F | BE | BOV | 3 | Unknown | DM, HPT | Chorioretinitis, Macular scar | Roth’s spots, Vitritis, DH, BH | BE posterior uveitis | IV benzylpenicillin 4 MU 4 hourly for 2 weeks | CF 2ft | CF 2ft | 6/90 | 6/24 | 40 |
| 5 | 67 | M | LE | BOV | 3 | Unknown | Nil | N | AC cells, vitritis, macular edema | LE panuveitis | IV benzylpenicillin 4 MU 4 hourly for 2 weeks | 6/9 | CF 2ft | 6/9 | 4/60 | 30 |
| 6 | 80 | F | BE | BOV | 3 | Unknown | HPT, IHD CKD, CVA | OD swelling, macular edema | OD swelling, peripheral chorioretinal atrophy | BE posterior uveitis, BE optic neuritis | IV benzylpenicillin 3 MU 4 hourly for 2 weeks | 3/60 | 6/60 | 6/21 | 6/7.5 | 12 |
| 7 | 76 | F | LE | Recurrent eye redness | 48 | Unknown | Nil | Senile cataract | PS, AC cells, ectropion uvea, senile cataract | LE anterior uveitis, RE cataract | IV benzylpenicillin 4 MU 4 hourly for 2 weeks | 1/60 | CF 2ft | 6/7.5 (Post cataract surgery) | CF 2ft | 12 |
| 8 | 75 | M | RE | BOV | 12 | Unknown | HPT, IHD | Vitritis | N | RE posterior uveitis | IV benzylpenicillin 3 MU 4 hourly for 2 weeks | CF 2ft | 6/15 | 6/24 | 6/15 | 4 |
| 9 | 60 | F | RE | BOV | 3 weeks | Sexual promiscuity | HPT | KP, PS, vitritis | N | RE panuveitis | IV benzylpenicillin 4 MU 4 hourly for 2 weeks | 6/60 | 6/9 | 6/36 | 6/9 | 3 |
| 10 | 72 | M | LE | BOV | 6 | Unknown | DM, HPT, thyroid adenoma | N | KP, vitritis | LE panuveitis | IV benzylpenicillin 4 MU 4 hourly for 2 weeks | 6/6 | 6/90 | 6/6 | 6/12 | 2 |
Serologic testing for syphilis and HIV status of patients with ocular syphilis
HIV, human immunodeficiency virus; ECLIA, electro-chemiluminescence immunoassays for syphilis; TP-PA, Treponema pallidum particle agglutination test; FTA-ABS, fluorescent treponemal antibody absorption test; RPR, rapid plasma reagin test; NR, non-reactive; R, reactive; NT, not tested
| Case | Syphilis ECLIA Titre | Syphilis TP-PA | FTA-ABS | Syphilis RPR | HIV status |
| 1 | 160 | NT | NT | 1/16 | Negative |
| 2 | 65 | Positive | NT | NR | Negative |
| 3 | NR | NT | R | NR | Negative |
| 4 | 283 | NT | NT | 1/4 | Negative |
| 5 | 86 | NT | NT | 1/4 | Negative |
| 6 | NT | NT | R | 1/2 | Negative |
| 7 | 66 | NT | NT | 1/4 | Negative |
| 8 | 103 | NT | NT | 1/8 | Negative |
| 9 | NT | Positive | NT | 1/2 | Negative |
| 10 | 68 | Positive | NT | 1/2 | Negative |
Comparison of current review with previous studies of ocular syphilis
N, number of patients; IV, intravenous; IM, intramuscular; HIV, human immunodeficiency virus; +ve, positive; -ve, negative; U, unavailable data; NS, not specified
| Variables | Current review | Sahin et al. [ | Kim et al. [ | Moradi et al. [ | Shen et al. [ | Oliver et al. [ | Yap et al. [ |
| Country/year | Malaysia/2017 | Turkey/2016 | Korea/2016 | US/2014 | China/2015 | US/2016 | Singapore/2014 |
| Duration (total in years) | 2013–2017 (5) | 2012–2014 (3) | 2002–2014 (12) | 1984–2014 (31) | 2009–2014 (6) | 2014–2015 (2) | 2004–2009 (6) |
| N (number of eyes) | 10 (13) | 12 (17) | 39 (45) | 35 (61) | 13 (21) | 388 (U) | 12 (18) |
| Population HIV +ve/-ve | HIV -ve | HIV -ve | HIV -ve | HIV +ve and HIV -ve | HIV +ve and HIV-ve | HIV +ve and HIV -ve | HIV +ve and HIV -ve |
| HIV +ve | 0 | 0 | 0 | 19 | 1 | 198 | 3 |
| HIV -ve | 10 | 12 | 39 | 16 | 12 | 190 | 7 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Mean/median age | 69.8 ± 6.4 | 43.8 | 61.0 ± 11.4 | 49.4 ± 16.5 | 50.3 ± 5.9 | 44.0 | 49.5 |
| Gender (%) | |||||||
| Male | 3 (30.0) | 7 (58.3) | 21 (53.8) | 26 (74.3) | 7 (53.8) | 362 (93.3) | 11 (91.7) |
| Female | 7 (70.0) | 5 (41.7) | 18 (46.2) | 9 (25.7) | 6 (42.9) | 26 (6.7) | 1 (8.3) |
| Symptoms (%) | |||||||
| Blurring of vision | 12 (85.7) | U | U | 17 (27.9) | 11(84.6) | 210 (64.4) | 11 (61.1) |
| Blind/visual loss | 0 (0) | U | U | 13 (21.3) | 0 (0) | 107 (32.8) | 0 (0) |
| Redness of eye or eye pain | 4 (30.8) | U | U | U | 2 (15.6) | 46 (14.1) | 5 (27.8) |
| Previous history of syphilis | 1 (10.0) | U | 15 (38.5) | 11 (31.4) | U | U | 2 (16.7) |
| Mean/median duration of symptoms | 11.4 ± 16.7 months | U | 2.4 weeks | 2 months | U | U | U |
| Mean/median follow up duration | 23.1 ± 18.2 months | 16.3 months | U | 9 months | 4.1 ± 5.8 months | U | 26 months |
| Sexual behaviour (%) | |||||||
| Heterosexual | 10 (100) | U | 11 (28.2) | U | U | U | 10 (83.3) |
| Bisexual | 0 (0) | U | 4 (10.3) | U | U | U | 2 (16.7) |
| MSM | 0 (0) | U | 3 (7.6) | 9 (25.7) | 0 (0) | 249 (68.8) | 0 (0) |
| Unknown | 0 (0) | U | 21 (53.8) | U | U | U | 0 (0) |
| Laterality (%) | |||||||
| Both eyes | 3 (30.0) | 5 (41.6) | 6 (15.3) | 26 (74.3) | 8 (61.5) | U | 6 (50) |
| Unilateral | 7 (70.0) | 7 (58.3) | 33 (84.6) | 9 (25.7) | 5 (38.4) | U | 6 (50) |
| Visual acuity presentation (%) | |||||||
| 6/12 or better | 1 (7.7) | 11 (64.7) | U | 31 (50.8) | 10 (47.6) | U | 7 (38.8) |
| 6/15 - 6/60 | 5 (38.5) | 5 (41.7) | U | 17 (27.9) | 8 (38.1) | U | 9 (50.0) |
| > 6/60 | 7 (53.8) | 1 (5.8) | U | 13 (21.3) | 1 (4.8) | U | 2 (11.1) |
| Unrecorded | 0 (0) | 0 (0) | U | 0 (0) | 2 (9.5) | U | 0 (0) |
| Clinical features (%) | |||||||
| Anterior uveitis | 2 (15.4) | 5 (29.4) | 3 (6.7) | 10 (16.4) | 1 (4.8) | NS | 6 (33.3) |
| Intermediate uveitis | 0 (0) | 2 (11.8) | 2 (4.4) | 2 (3.3) | 0 (0) | NS | 1 (5.6) |
| Anterior uveitis and intermediate uveitis | 0 (0) | 0 (0) | 0 (0) | 12 (9.7) | 0 (0) | NS | 0 (0) |
| Posterior uveitis | 7 (53.8) | 5 (29.4) | 17 (37.8) | 5 (8.2) | 13 (61.9) | 20 (12.7) | 5 (27.8) |
| Posterior uveitis and intermediate uveitis | 0 (0) | 0 (0) | 3 (6.7) | 0 (0) | 0 (0) | NS | 0 (0) |
| Panuveitis | 4 (30.8) | 2 (11.8) | 13 (28.9) | 28 (45.9) | 2 (9.5) | NS | 6 (33.3) |
| Optic nerve involvement | 2 (15.4) | 1 (5.9) | 5 (11.1) | 8 (13.6) | 5 (23.8) | 18 (11.4) | 6 (33.3) |
| Retinal detachment | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 6 (3.8) | 0 (0) |
| Scleritis | 0 (0) | 2 (11.8) | 0 (0) | 4 (6.5) | 0 (0) | 0 (0) | 0 (0) |
| Treatment (%) | |||||||
| IV penicilin | 9 (90.0) | 10 (83.3) | 0 (0) | 24 (68.6) | 0 | 230 (59.3) | 8 (66.7) |
| IM penicilin | 1 (10.0) | 0 (0) | 14 (35.9) | 1 (2.9) | 3 (23.0) | NS | 4 (33.3) |
| IV and IM penicilin | 0 (0) | 0 (0) | 10 (25.6) | 7 (20.0) | 2 (15.4) | NS | 0 (0) |
| Other antibiotics regime | 0 (0) | 2 (16.7) | 15 (38.5) | 1 (2.9) | 7 (53.8) | NS | 0 (0) |
| No treatment/Unrecorded | 0 (0) | 0 (0) | 0 (0) | 2 (5.7) | 1 (7.7) | 12 (3.1) | 0 (0) |
| Visual acuity final (%) | |||||||
| 6/12 or better | 4 (30.8) | 13 (76.4) | U | 36 (59.0) | 1 (4.8) | U | 14 (77.8) |
| 6/15 - 6/60 | 5 (38.5) | 4 (23.5) | U | 11 (18.0) | 11 (52.4) | U | 3 (16.7) |
| > 6/60 | 4 (30.8) | 0 (0) | U | 7 (11.4) | 1 (4.8) | U | 1 (5.6) |
| Unrecorded | 0 (0) | 0 (0) | U | 7 (11.4) | 8 (38.1) | U | 0 (0) |
| Recurrence | 2 (20.0) | 0 (0) | 1 (2.2) | U | U | U | 2 (16.7) |